Rival permanent heart implants enter human trials
This article was originally published in Clinica
Executive Summary
US company Arrow International last week announced the first clinical implant of its permanent heart replacement device for patients with end-stage heart failure. At the same time, its competitor Abiomed said that it was ready to start human trials of its permanent device, assuming it gets regulatory approval, now that it is producing clinically configured versions of the AbioCor pump.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.